GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Lyell Immunopharma
Lyell Immunopharma is a biotech company working to improve the effectiveness of cell-based cancer therapy. Its stock price represents a venture bet on its scientific developments. The chart reflects high volatility and dependence on preclinical and clinical trial data.
Share prices of companies in the market segment - Oncology immuno-therapy
Lyell Immunopharma is a biotech company developing T-cell-based cell therapies for the treatment of solid tumors. We've categorized it as "Immuno-Oncology," and the chart below shows how investors view this cutting-edge, yet high-risk, sector in the fight against cancer.
Broad Market Index - GURU.Markets
Lyell Immunopharma is a biotech company developing T-cell-based cell therapies for the treatment of solid tumors. We've categorized it as "Immuno-Oncology," and the chart below shows how investors view this cutting-edge, yet high-risk, sector in the fight against cancer.
Change in the price of a company, segment, and market as a whole per day
LYEL - Daily change in the company's share price Lyell Immunopharma
For Lyell, an immunotherapy company, change_co is a measure of reaction to clinical and regulatory news. Daily fluctuations reflect the volatility associated with cell therapy development. This metric is a key element in analyzing young biotech companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Lyell Immunopharma, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with LYEL, which focuses on cell therapy, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Lyell is a biopharmaceutical company developing cell therapies for cancer. The cell therapy sector is one of the most advanced and volatile in biotech. The chart below shows the average daily fluctuations in this industry, serving as a benchmark for evaluating Lyell's highly volatile stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Lyell Immunopharma
Lyell Immunopharma's year-over-year performance is a story of efforts to overcome key barriers in cancer cell therapy. Its 12-month market cap depends entirely on early clinical trial data, where the company must prove that its technologies can improve the longevity and effectiveness of T cells against solid tumors.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Lyell Immunopharma, Inc. is a clinical-stage biotechnology company developing cell therapies for the treatment of solid tumors. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this complex area of oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Lyell Immunopharma is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new cell therapy trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Lyell Immunopharma
The value of Lyell, a cell therapy company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of its unique technologies for improving the effectiveness of cancer cell therapy, which determines its future.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Lyell Immunopharma is a biotech company seeking to overcome key barriers in cell therapy for hard-to-treat solid tumors. The chart below illustrates the general sentiment in the immuno-oncology sector, where Lyell is working to address one of the most challenging areas.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Lyell Immunopharma is a biotech company working to improve cell therapy for solid tumors. Its shares represent a venture capital investment in breakthrough medical technologies. Its performance is completely unrelated to the market and is determined by scientific successes and failures.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Lyell Immunopharma
Shares of Lyell Immunopharma, which is working to improve cancer cell therapy, are extremely volatile. Weekly price movements depend entirely on news about the progress of their preclinical and clinical trials aimed at improving the efficacy of CAR-T cells. The chart below illustrates how short-term scientific events shape biotech valuations.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
How does Lyell Immunopharma's performance compare to the broader biotech sector? This chart compares the weekly stock price of this cell therapy company with the overall trend. This helps us understand whether its movement is the result of a unique scientific breakthrough or a reflection of overall investor sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Lyell Immunopharma is a biotech company working to improve the effectiveness of cell therapy for cancer. This chart shows how its weekly performance is detached from the market. Its stock price moves are driven by news about clinical trials and scientific progress, not the overall economic situation.
Market capitalization of the company, segment and market as a whole
LYEL - Market capitalization of the company Lyell Immunopharma
Lyell Immunopharma's market cap is a bet on its scientific approach to overcoming one of the main challenges in cancer cell therapy: T-cell exhaustion. The company's valuation hinges on the success of its clinical trials. The chart illustrates how investors assess its chances of developing more durable and effective treatments.
LYEL - Share of the company's market capitalization Lyell Immunopharma within the market segment - Oncology immuno-therapy
Lyell Immunopharma is a biotech company whose market share is based on its research into overcoming T-cell exhaustion to improve the effectiveness of cell-based cancer therapy. Its market capitalization reflects its scientific strength.
Market capitalization of the market segment - Oncology immuno-therapy
The chart below shows the combined market capitalization of biotech companies working to improve the effectiveness of cell therapy. Lyell Immunopharma is one of the most ambitious players. The dynamics in the chart reflect the enormous scientific and financial stakes involved in the effort to defeat solid tumors.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart depicts the market value of a company fighting one of the main challenges in oncology—T-cell exhaustion. Lyell Immunopharma's market value reflects its belief in its scientific approaches to enhancing cell therapy. The line shows how cutting-edge science is trying to carve out a stake in the future of cancer treatment.
Book value capitalization of the company, segment and market as a whole
LYEL - Book value capitalization of the company Lyell Immunopharma
The graph below shows Lyell Immunopharma's scientific foundation. Its line reflects the value of intellectual property for technologies to improve the effectiveness of cell therapy for solid tumors, as well as cash reserves for clinical trials. An increase in the graph signifies progress in solving one of the most complex problems in oncology.
LYEL - Share of the company's book capitalization Lyell Immunopharma within the market segment - Oncology immuno-therapy
Lyell Immunopharma's core assets are its advanced R&D centers and manufacturing facilities, focused on addressing T-cell depletion to improve the effectiveness of cancer cell therapy. The chart reflects its share of this high-tech scientific and manufacturing infrastructure.
Market segment balance sheet capitalization - Oncology immuno-therapy
Below you can see the overall book value of the biotech sector. Compared to this, Lyell, which is developing new approaches to cell therapy, looks like a lightweight. Its capital comes not from factories, but from cutting-edge science. Its balance sheet is modest compared to its ambitions to create more effective "living medicines."
Book value of all companies included in the broad market index - GURU.Markets
Lyell Immunopharma is a biotech company focused on improving cell therapy for cancer. The company's assets are not factories, but cutting-edge scientific platforms and research data. The company's balance sheet is invested in the creation of the "next generation" of cell-based therapies that will work more effectively in the body.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Lyell Immunopharma
Lyell's balance sheet is characterized by its enormous cash reserves. Its market capitalization, which is not much higher than these reserves, shows that investors are highly skeptical of its scientific platform after less-than-convincing data. The MvsBCap_Co chart ≈ 1 indicates the company's valuation as a "research institute with a large grant fund."
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Lyell Immunopharma is a biotech company working to improve cell therapy for solid tumors. Its value lies in its scientific approach. The chart shows a speculative estimate of its potential to solve one of the most complex problems in oncology, which far exceeds its tangible assets.
Market to book capitalization ratio for the market as a whole
Lyell Immunopharma is a biotech company striving to overcome key barriers to successful cell therapy for solid tumors. Its value lies in its scientific research. This chart illustrates why investors are willing to pay a premium for innovative approaches in oncology, even in the early stages.
Debts of the company, segment and market as a whole
LYEL - Company debts Lyell Immunopharma
Lyell Immunopharma, a biotech focused on cell therapy for solid tumors, uses debt to solve complex scientific problems. This chart shows how the company raises capital to conduct expensive research and clinical trials. In this highly complex field of oncology, debt fuels scientific discovery.
Market segment debts - Oncology immuno-therapy
Lyell Immunopharma is a biotech company working to develop more effective and durable cell therapies for the treatment of solid tumors, one of the most challenging areas in oncology. This chart shows how the company funds its ambitious research, which requires significant and long-term capital.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Lyell Immunopharma
Lyell Immunopharma is a company developing cell therapies for solid tumors. This chart shows its reliance on external funding. In the highly competitive and capital-intensive field of oncology, debt is a significant risk, as success depends on the outcome of lengthy and expensive clinical trials.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Lyell Immunopharma is a biotech company working to improve the properties of T cells to enhance the effectiveness of cell-based cancer therapy. This fundamental research requires significant capital. The chart shows how the company's debt burden compares to the market capitalization and risk of the overall immuno-oncology sector.
Debt to book value of all companies in the market
Lyell Immunopharma (LYEL) is developing cell therapies for solid tumors, one of the most challenging areas in oncology. This chart shows the overall debt burden of the economy. It serves as a contrast to Lyell's financial model, which, during the R&D phase, is entirely dependent on capital from investors who believe in its scientific breakthroughs.
P/E of the company, segment and market as a whole
P/E - Lyell Immunopharma
This metric for Lyell Immunopharma, a biotech company working to improve cell therapy for solid tumors, is a bet on a scientific breakthrough. There is no P/E ratio. The valuation depends on the success of its technologies in overcoming key barriers that hinder the effectiveness of current cancer immunotherapies.
P/E of the market segment - Oncology immuno-therapy
This chart illustrates the average P/E for biotech companies. For Lyell Immunopharma, which is working on the complex challenge of treating solid tumors, it serves as a backdrop. It shows the overall level of optimism in immuno-oncology, providing context for Lyell's valuation, which is a bet on its breakthrough scientific approaches.
P/E of the market as a whole
Lyell Immunopharma is a biotech company focused on developing cell therapies for the treatment of solid tumors, one of the most challenging areas in oncology. The company is working to overcome barriers that limit the effectiveness of existing treatments. This chart helps understand how the market values breakthrough but risky technologies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Lyell Immunopharma
Lyell Immunopharma is a biotechnology company focused on developing cell therapies for the treatment of solid tumors, one of the most challenging areas in oncology. This chart shows the expected breakthrough in this field. The assessment depends on the success of its scientific approaches aimed at overcoming T-cell exhaustion and the results of clinical trials.
%20P%2FE%20Lyell%20Immunopharma&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Lyell-Immunopharma&v=1772702736436 "Chart of the company's future (projected) P/E Lyell Immunopharma")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Lyell Immunopharma is a biotech company working to improve the properties of T cells to enhance the effectiveness of cancer cell therapy. This chart reflects the company's long-term profitability expectations and shows how the market views their research and development efforts aimed at overcoming the key limitations of existing CAR-T therapies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772702736447 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Lyell Immunopharma is a biotech company working to improve cell therapy for solid tumors. Its success depends on scientific breakthroughs. This market expectations chart is important as an indicator of investor risk appetite. Growing market optimism makes it easier for Lyell to raise the funds needed for long-term clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772702736453 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Lyell Immunopharma
Lyell Immunopharma is a biotechnology company developing cell therapy (CAR-T) for the treatment of solid tumors, one of the most challenging areas in oncology. Its financial results reflect significant investments in research aimed at overcoming the barriers that limit current treatments.
Profit of companies in the market segment - Oncology immuno-therapy
Lyell Immunopharma is working to improve the efficacy of cell therapy for solid tumors, a key challenge in oncology. The company is currently in the research phase. This growth rate for the biotech sector reflects the enormous scientific and financial efforts being made to address fundamental problems in medicine, which determines the industry's future profitability.
Overall market profit
Lyell Immunopharma is a biotech company working to improve cell therapy for solid tumors. This is one of the most challenging areas in oncology. Lyell's future depends solely on scientific breakthroughs in its laboratories. Its history is unrelated to the economic cycles that shape the overall picture in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Lyell Immunopharma
Lyell Immunopharma is a biotechnology company focused on overcoming key barriers in cell therapy for solid tumors. This graph shows expectations, which depend entirely on the clinical progress of its innovative approaches. Success in treating difficult-to-treat cancers could dramatically change prognoses.
%20profit%20of%20the%20company%20Lyell%20Immunopharma&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Lyell-Immunopharma&v=1772702736496 "Graph of future (projected) profit of the company Lyell Immunopharma")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Lyell Immunopharma is a biotechnology company working to improve the effectiveness of cell therapy (T-cell therapy) for the treatment of solid tumors. This chart shows the revenue forecast for the immuno-oncology sector. It reflects expectations for breakthroughs in cancer treatment. This background is important for assessing the potential of Lyell's technologies to overcome T-cell exhaustion.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772702736500 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Lyell Immunopharma is a biotech company focused on developing cell therapies for solid tumors, a complex undertaking. Its future depends on scientific breakthroughs and investment. The economic backdrop illustrated here influences investor risk appetite and the availability of capital to fund breakthrough, but very expensive, medical research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772702736512 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Lyell Immunopharma
Lyell Immunopharma is a biotech company seeking to overcome key barriers to cell therapy's effectiveness in treating solid tumors. This chart shows how investors view its cutting-edge science, which could significantly expand the application of cell therapy, focusing on future breakthroughs rather than current revenue.
P/S market segment - Oncology immuno-therapy
Lyell Immunopharma is a biotechnology company developing cell therapies for the treatment of solid tumors. The company is working to overcome key barriers that prevent existing cell therapies from being effective against these cancers. This chart shows the average valuation for the sector, helping to understand how the market values Lyell's cutting-edge scientific developments.
P/S of the market as a whole
Lyell Immunopharma is a biotech company working to improve the effectiveness of cell therapy (T-cells) for the treatment of solid tumors, a key challenge in oncology. This is cutting-edge science with high risk. This total market valuation chart helps understand the premium investors are paying for this potentially revolutionary but risky revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Lyell Immunopharma
Lyell Immunopharma is a biotech company working to improve cell therapy for solid tumors. While in the research stage, it is evaluated based on its future potential. This chart shows investor expectations that its technology will overcome the current limitations of CAR-T therapy.
%20P%2FS%20Lyell%20Immunopharma&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Lyell-Immunopharma&v=1772702736558 "The graph of the company's future (projected) P/S Lyell Immunopharma")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Lyell Immunopharma is a biotech company developing technologies to improve cell therapy for solid tumors. This chart compares market expectations for its future revenue with other oncology companies. The valuation reflects investor confidence in its scientific approaches to overcoming key barriers in cell therapy.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772702736559 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Lyell Immunopharma is a biotech company working to improve cell therapies for the treatment of solid tumors. This is one of the most challenging areas in oncology. Market optimism, evident in this chart, is helping companies like Lyell attract the significant investment needed to solve fundamental scientific problems.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772702736563 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Lyell Immunopharma
Lyell Immunopharma is a biotech company working to develop more effective cell therapy (T-cells) for the treatment of solid tumors. While in clinical development, its revenue is generated through collaborations with other pharmaceutical companies. The chart shows the funding that allows the company to address one of the most complex challenges in oncology.
Sales of companies in the market segment - Oncology immuno-therapy
Lyell Immunopharma is a biotech company focused on developing cell therapies for the treatment of solid tumors. Its scientific platforms are designed to overcome key barriers that hinder the effectiveness of existing T-cell therapies. Currently, there are no revenues. This chart demonstrates the enormous investor interest in the next generation of immuno-oncology.
Overall market sales
Lyell Immunopharma is a biotech company working to develop more effective cell therapies for the treatment of solid tumors. Its prospects depend entirely on success in the laboratory and clinical trials. The economic situation, reflected in the chart, affects the availability of venture capital needed to finance such ambitious projects.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Lyell Immunopharma
Lyell Immunopharma is a biotechnology company working to improve the effectiveness of cell therapy (T-cells) for the treatment of solid tumors, one of the biggest challenges in oncology. This chart reflects analysts' confidence in Lyell's scientific approaches and their potential to create breakthrough cancer treatments.
%20sales%20of%20the%20company%20Lyell%20Immunopharma&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Lyell-Immunopharma&v=1772702736619 "Schedule of future (projected) sales of the company Lyell Immunopharma")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Lyell Immunopharma is a biotechnology company working to improve the efficacy of cell therapy for solid tumors. This chart provides an outlook for the immuno-oncology sector. It assesses whether Lyell's scientific approach can overcome the key challenges limiting the use of CAR-T therapy in the treatment of the most common cancers.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772702736634 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Lyell Immunopharma is a biotech company working to improve cell therapies for the treatment of solid tumors. This chart, reflecting the investment climate in oncology, is critically important. Lyell's ability to attract funding for its cutting-edge and expensive research directly depends on investor confidence in the company's future success.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772702736660 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Lyell Immunopharma
Lyell Immunopharma is a biotech company focused on developing cell therapies for solid tumors, which are challenging targets for current treatments. Its business is driven by high-cost research. This chart reflects the significant investment in science required to overcome barriers in immuno-oncology.
Market segment marginality - Oncology immuno-therapy
Lyell Immunopharma is a biotech company working to improve the effectiveness of cell therapy (T-cell therapy) for the treatment of solid tumors, a major challenge in oncology. This chart reflects their significant investment in research aimed at overcoming T-cell exhaustion, which could lead to a breakthrough in cancer treatment.
Market marginality as a whole
Lyell Immunopharma is a biotech company developing technologies to improve cell therapy for solid tumors, one of the most challenging areas in oncology. The overall picture of profitability is irrelevant to them. Their future depends on the success of their breakthrough scientific ideas in the clinic. This is a bet on solving a fundamental problem in cancer treatment.
Employees in the company, segment and market as a whole
Number of employees in the company Lyell Immunopharma
Lyell Immunopharma is a biotech company seeking to address the problem of T-cell exhaustion to develop more effective cell therapies for solid tumors. This graph shows a large team of scientists. The scale of the team reflects the complexity and capital intensity of research in this cutting-edge field of oncology.
Share of the company's employees Lyell Immunopharma within the market segment - Oncology immuno-therapy
Lyell Immunopharma is a biotech company focused on overcoming key barriers to curing solid tumors with cell therapy. This chart shows the percentage of leading immuno-oncology scientists the company attracts. It's a testament to its ambitious goal and the scale of the research team working on this complex task.
Number of employees in the market segment - Oncology immuno-therapy
Lyell Immunopharma is a biotech company working to improve the effectiveness of cell therapy (T-cell therapy) for the treatment of solid tumors. The chart shows the growth in employment in the immuno-oncology sector. The increase in the number of scientists reflects efforts to overcome one of the main challenges in this field and create more resilient T-cells to fight cancer.
Number of employees in the market as a whole
Lyell Immunopharma is a biotechnology company focused on developing cell therapies for solid tumors, which are challenging targets for existing treatments. This employment chart shows innovative companies like Lyell at the forefront of oncology, creating jobs for world-leading immunology scientists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Lyell Immunopharma (LYEL)
Lyell Immunopharma, Inc. is a biotech company developing cell therapies for the treatment of solid tumors. Its value is based entirely on its scientific potential. This chart illustrates a model where intellectual capital dominates. A small team of scientists can create a platform worth billions of dollars, resulting in an extremely high market capitalization per employee.
%20of%20the%20company%20Lyell%20Immunopharma%20(LYEL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Lyell-Immunopharma-LYEL&v=1772702736809 "Chart of market capitalization per employee (in thousands of dollars) of the company Lyell Immunopharma (LYEL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Lyell Immunopharma is a biotech company working to improve the effectiveness of cell therapy for solid tumors, a major challenge in oncology. This indicator reflects investor hopes for a scientific breakthrough. The chart shows the value the market attributes to each scientist working on this complex task.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772702736812 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Lyell Immunopharma is a biotech company working to improve cell therapy (T-cell therapy) for solid tumors, one of the most challenging areas in oncology. This chart reflects the market's high appreciation for their scientific approach, with the cost per employee reflecting their hopes for a breakthrough in cancer treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772702736816 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Lyell Immunopharma (LYEL)
Lyell Immunopharma (LYEL) is a biotech company focused on developing cell therapy (T-cells) for solid tumors, the "holy grail" of oncology. This chart shows the high "cost" of this R&D—the negative profit margin (expense) per scientist.
%20Chart%20Lyell%20Immunopharma%20(LYEL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Lyell-Immunopharma-LYEL&v=1772702736826 "Company Profit Per Employee (in thousands of dollars) Chart Lyell Immunopharma (LYEL)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Lyell Immunopharma is a biotech company focused on developing cell therapies (T-cells) for the treatment of solid tumors. Their primary goal is to overcome T-cell exhaustion. This chart demonstrates the benchmark performance of biotech personnel and is essential for assessing how effectively Lyell's scientific team is addressing this complex challenge.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772702736854 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Lyell Immunopharma is a biotech company working to address the problem of T-cell exhaustion, a major hurdle in cancer cell therapy. It has extensive R&D. The chart illustrates the high cost of research (negative profit) per employee in the effort to develop next-generation CAR-T therapy.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772702736867 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Lyell Immunopharma (LYEL)
Lyell Immunopharma is a biotech company working to improve cell therapy (CAR-T) for the treatment of solid tumors. This chart reflects its focus on cutting-edge research. Zero revenue per employee is the norm for a clinical-stage company tackling one of the most complex challenges in modern oncology.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Lyell-Immunopharma-LYEL&v=1772702736889 "Sales chart per company employee Lyell Immunopharma (LYEL)")
Sales per employee in the market segment - Oncology immuno-therapy
Lyell Immunopharma (LYEL) is a biotech company developing cell therapies (CAR-T) for the treatment of solid tumors, attempting to overcome T-cell depletion. This chart shows the revenue (from partnerships) generated by each employee (scientist). It is an indicator of the productivity of their cutting-edge immuno-oncology R&D platform.
Sales per employee for the market as a whole
Lyell Immunopharma is a biotech company seeking to solve the main problem with CAR-T cell therapy—T-cell exhaustion, which hinders the treatment of solid tumors. They are a clinical-stage R&D company with no revenue. This near-zero graph reflects their investment in cutting-edge science: their research staff is working on developing the next generation of cell therapy.
Short shares by company, segment and market as a whole
Shares shorted by company Lyell Immunopharma (LYEL)
Lyell Immunopharma is a biotech company trying to improve cell therapy (CAR-T) for the treatment of solid tumors. This chart shows bearish bets. The shorts are driven by the fact that solid tumors are the "holy grail" for CAR-T, and no one has yet successfully treated them with this method. The risk of failure is very high.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Lyell-Immunopharma-LYEL&v=1772702737025 "Short Shares Chart for the Company Lyell Immunopharma (LYEL)")
Shares shorted by market segment - Oncology immuno-therapy
Lyell Immunopharma (LYEL) is a clinical-stage biotech company seeking to improve cell therapy (CAR-T) for the treatment of solid tumors by overcoming T-cell exhaustion. This chart shows the odds against the entire biotech sector. The rising odds against the industry reflect investor skepticism about the success of this complex technology and a lack of funding.
Shares shorted by the overall market
Lyell Immunopharma (LYEL) is a clinical-stage biotech focused on developing cell therapy (T-cells) for solid tumors. This is an extremely challenging task. This market fear chart shows when investors are risk-averse. LYEL shares, a "breakout bet," are selling off.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Lyell Immunopharma (LYEL)
Lyell Immunopharma is a biotech company focused on cell therapy. Its shares are highly volatile and dependent on R&D. This chart can surge above 70 on positive trial data or partnerships. Oversold levels (<30) are often associated with setbacks, delays, or a general downturn in biotech, causing investor panic.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Lyell-Immunopharma-LYEL&v=1772702737197 "RSI 14 indicator chart for the company's stock Lyell Immunopharma (LYEL)")
RSI 14 Market Segment - Oncology immuno-therapy
Lyell Immunopharma is a biotech company seeking to address one of the key challenges in cell therapy: T-cell exhaustion. Its goal is to make immunotherapy effective against solid tumors. This chart shows the overall "temperature" in the volatile immuno-oncology sector. It helps separate LYELL's performance from the general "hype" or "disappointment" in the field.
RSI 14 for the overall market
Lyell Immunopharma (LYEL) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LYEL (Lyell Immunopharma)
Lyell Immunopharma is a biotech company developing cell therapy (T-cell therapy) for solid tumors, using technologies to overcome T-cell exhaustion. This chart shows the average analyst forecast. Their targets are based on clinical data and the potential of their breakthrough technologies in immuno-oncology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LYEL-Lyell-Immunopharma&v=1772702737318 "A chart showing analyst consensus forecasts for the expected stock price. LYEL (Lyell Immunopharma)")
The difference between the consensus estimate and the actual stock price LYEL (Lyell Immunopharma)
Lyell Immunopharma (LYEL) is a biotech company developing next-generation T-cell therapy (CAR-T) for the treatment of solid tumors that are currently resistant to these therapies. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting whether analysts believe their drug can effectively treat solid tumors.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LYEL-Lyell-Immunopharma&v=1772702737336 "A chart showing the difference between the consensus forecast and the actual stock price. LYEL (Lyell Immunopharma)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Lyell Immunopharma (LYEL) is a biotech company attempting to recharge cell therapy (T-cells) to combat hard tumors (lung and breast cancer) that are currently resistant to it. This chart shows general expectations for the immunotherapy sector. It reflects whether experts believe a breakthrough in solid tumor treatment is possible.
Analysts' consensus forecast for the overall market share price
Lyell Immunopharma is a biotech company working to enhance the viability of T cells to make cell therapy (CAR-T) effective against solid tumors. This chart shows the overall risk appetite. For Lyell, which is solving one of the major problems in oncology, overall market optimism (a rising chart) is absolutely necessary to fund expensive research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Lyell Immunopharma
Lyell Immunopharma is a biotech company working on the Holy Grail of cell therapy: the treatment of solid tumors. Their R&D platform aims to overcome T-cell exhaustion so they can attack cancer longer. This chart is a clear indicator of faith in their cutting-edge science, reflecting the market's appreciation of their (very early) clinical data.
AKIMA Market Segment Index - Oncology immuno-therapy
Lyell Immunopharma is a biotech company seeking to overcome key barriers in cell therapy (CAR-T) for the treatment of solid tumors. This chart shows the average index for the immunotherapy sector. It helps investors assess how Lyell's scientific approach to cell reprogramming compares to the industry average.
The AKIM Index for the overall market
Lyell Immunopharma is a biotech company developing exhaustion-resistant T-cell therapies (CAR-T) for the treatment of solid tumors. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding efforts to defeat the most challenging cancers.
